logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Evaluation of the World Health Organisation antibody-testing strategy for the individual patient diagnosis of HIV infection (strategy III).

    Article - En anglais

    Objective

    To evaluate the World Health Organisation (WHO) antibody testing strategy for the individual patient diagnosis of HIV infection (strategy III).

    Design

    Evaluation of a combination of enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to HIV-1 and HIV-2 infection.

    The WHO strategy III calls for a combination of three ELISAs, based on different antigens and/or differing test principles, to be used in a sequential fashion.

    The first part of the study evaluated various kits as part of a selection process.

    The second part of the study was an assessment of the three-ELISA testing strategy on routine sera submitted to the National Institute for Virology (NIV) for HIV testing.

    In all instances, the conventional testing protocol, which utilises a screening ELISA followed by a confirmatory Western blot (WB) on positive specimens, was used as the'gold standard'Setting.

    The HIV-testing laboratory at the NIV, Johannesburg.

    Results

    In the first part of the study, all of the ELISA kits evaluated showed high sensitivity and specificity, and a selection of the kits for part two of the study was made in accordance with the WHO recommendation.

    The kits selected, in order of use, were the Biotest anti-HIV 1/2 (test 1), Pasteur Genelavia Mixt HIV-1/2 (test 2) and Murex Wellcozyme HIV-1 competitive assay (test 3).

    This combination was evaluated using 7 812 sera submitted to the NIV for serology testing.

    Mots-clés Pascal : SIDA, Virose, Infection, Virus HIV1, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Virus HIV2, Evaluation, Technique ELISA, Anticorps, OMS, Homme, République Sud Africaine, Afrique, Immunopathologie, Immunodéficit, Protocole diagnostic

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, HIV-1 virus, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, HIV-2 virus, Evaluation, ELISA assay, Antibody, WHO, Human, South Africa, Africa, Immunopathology, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0591666

    Code Inist : 002B06D01. Création : 01/03/1996.